Art

J-GLOBAL ID：202102246226921413   Reference number：21A0802598

Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development

急性骨髄性白血病における進展: 最近の承認治療と開発における薬剤【JST・京大機械翻訳】

Author (6)： Stanchina Michele (Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA) ,  Soong Deborah (Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA) ,  Soong Deborah (Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL 33136, USA) ,  Zheng-Lin Binbin (Department of Medicine, Icahn School of Medicine Mount Sinai West-Morningside, New York, NY 10025, USA) ,  Watts Justin M. (Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA) ,  Taylor Justin (Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA)
Material： Cancers (Web)
Volume： 12  Issue： 11  Page： 3225  Publication year： 2020 
JST Material Number： U7153A  ISSN： 2072-6694  Document type： Article
Article type： 文献レビュー  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Acute myeloid leukemia (AML) i...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0802598&from=J-GLOBAL&jstjournalNo=U7153A") }}

Thesaurus term： consolidation(ground) ,  heredity ,  antibody ,  vaccine ,  drug therapy ,  complex(substance) ,  liposome ,  T cell ,  immunotherapy ,  prognosis ,  *acute myeloid leukemia ,  nitrogen heterocyclic compound ,  pyrimidine nucleoside ,  urea compound ,  furanoside
Semi thesaurus term： 悪性腫瘍 ,  低用量 ,  同種造血幹細胞移植 , 【Automatic Indexing@JST】

Author keywords (10)： novel therapeutics AML ,  FLT3 ,  IDH1/2 ,  CD33 ,  BCL2 ,  CD47 ,  CD123 ,  hedgehog ,  anti-body drug conjugate ,  immunotherapy

JST classification (2)： Blood cell tumors(=neoplasms)  (GK04000M) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (1)： Cytarabine

Reference (107)：

• Shlush, L.I.; Zandi, S.; Mitchell, A.; Chen, W.C.; Brandwein, J.M.; Gupta, V.; Kennedy, J.A.; Schimmer, A.D.; Schuh, A.C.; Yee, K.W.; et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014, 506, 328-333.
• Welch, J.S.; Ley, T.J.; Link, D.C.; Miller, C.A.; Larson, D.E.; Koboldt, D.C.; Wartman, L.D.; Lamprecht, T.L.; Liu, F.; Xia, J.; et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150, 264-278.
• Roboz, G.J.; DiNardo, C.D.; Stein, E.M.; de Botton, S.; Mims, A.S.; Prince, G.T.; Altman, J.K.; Arellano, M.L.; Donnellan, W.; Erba, H.P.; et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood 2020, 135, 463-471.
• Arlin, Z.; Case, D.C., Jr.; Moore, J.; Wiernik, P.; Feldman, E.; Saletan, S.; Desai, P.; Sia, L.; Cartwright, K. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 1990, 4, 177-183.
• Cortes, J.E.; Dombret, H.; Merchant, A.; Tauchi, T.; DiRienzo, C.G.; Sleight, B.; Zhang, X.; Leip, E.P.; Shaik, N.; Bell, T.; et al. Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncol. 2019, 15, 3531-3545.

Terms in the title (6)： 急性骨髄性白血病 ,  進展 ,  承認 ,  治療 ,  開発 ,  薬剤